Stanford spin-out Fibralign announced today that it entered into a long-term distributor agreement with Terumo for the BioBridge collagen matrix.
The agreement is set to see Terumo market and distribute BioBridge collagen matrix, which is used to treat and prevent secondary lymphedema, in Japan.
BioBridge is a sterile, implantable, biocompatible and biodegradable surgical mesh made from collagen and created with Fibralign’s Nanoweave technology. It has FDA 510(k) clearance for use in surgery to reinforce and repair soft tissue where weakness and deficiencies exist, according to a news release.
Union City, Calif.-based Fibralign touted preclinical studies that support the use of BioBridge in damaged lymphatic vessels. The company is currently pursuing approval in the U.S., Europe and elsewhere to market BioBridge for addressing lymphedema.
Fibralign and Terumo are engaged in an ongoing collaboration for commercializing BioBridge in Japan. Ter…